Skip to main content
Erschienen in: Zeitschrift für Gerontologie und Geriatrie 6/2022

18.07.2022 | Themenschwerpunkt

Pharmakologische Therapie kardiologischer Erkrankungen im Alter

Geriatrische Perspektive

verfasst von: Univ.-Prof. Dr. med. univ. Markus Gosch

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Kardiovaskuläre Erkrankungen haben die höchste Prävalenz im fortgeschrittenen Lebensalter. Trotzdem sind höhere Altersgruppen in Randomized Controlled Trials (RCT) häufig unterrepräsentiert. Die Folge ist eine in vielen Fällen ungenügende Evidenz. Empfehlungen aus Leitlinien können daher nur bedingt auf diese Altersgruppe übertragen werden. Aufgrund der Komplexität und Vulnerabilität geriatrischer Patienten bedarf es häufig individueller Überlegungen in der pharmakologischen Therapie. Im vorliegenden Beitrag wird die Pharmakotherapie einiger relevanter kardiovaskulärer Erkrankungen aus der Perspektive eines geriatrischen Behandlungsansatzes diskutiert.
Literatur
1.
Zurück zum Zitat Rottlaender D, Scherner M, Schneider T, Erdmann E (2007) Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr 132(4):139–144PubMedCrossRef Rottlaender D, Scherner M, Schneider T, Erdmann E (2007) Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr 132(4):139–144PubMedCrossRef
2.
Zurück zum Zitat Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P (2012) Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. Plos One 7(3):e33559PubMedPubMedCentralCrossRef Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P (2012) Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. Plos One 7(3):e33559PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146–M156PubMedCrossRef Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146–M156PubMedCrossRef
4.
Zurück zum Zitat Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM, Group HS (2008) Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 168(17):1890–1896PubMed Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM, Group HS (2008) Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 168(17):1890–1896PubMed
5.
Zurück zum Zitat Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P et al (2007) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63(2):136–147PubMedCrossRef Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P et al (2007) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63(2):136–147PubMedCrossRef
6.
Zurück zum Zitat Laroche ML, Charmes JP, Nouaille Y, Picard N, Merle L (2007) Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 63(2):177–186PubMedCrossRef Laroche ML, Charmes JP, Nouaille Y, Picard N, Merle L (2007) Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 63(2):177–186PubMedCrossRef
7.
Zurück zum Zitat Weingart C, Wirnsberger GH (2021) Clinical implications of the estimated glomerular filtration rate. Z Gerontol Geriatr 54(3):205–210PubMedCrossRef Weingart C, Wirnsberger GH (2021) Clinical implications of the estimated glomerular filtration rate. Z Gerontol Geriatr 54(3):205–210PubMedCrossRef
8.
Zurück zum Zitat Gosch MHH (2014) Pharmakotherapie. In: Pantel S, Bollheimer, Sieber, Kruse (Hrsg) Praxishandbuch Altersmedizin. Kohlhammer, Stuttgart, S 642–650 Gosch MHH (2014) Pharmakotherapie. In: Pantel S, Bollheimer, Sieber, Kruse (Hrsg) Praxishandbuch Altersmedizin. Kohlhammer, Stuttgart, S 642–650
9.
Zurück zum Zitat Chudiak A, Uchmanowicz I, Mazur G (2018) Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. Clin Interv Aging 13:1409–1418PubMedPubMedCentralCrossRef Chudiak A, Uchmanowicz I, Mazur G (2018) Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. Clin Interv Aging 13:1409–1418PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849–1860CrossRef Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849–1860CrossRef
11.
Zurück zum Zitat Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC et al (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303(9):841–848PubMedCrossRef Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC et al (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303(9):841–848PubMedCrossRef
12.
Zurück zum Zitat Bibbins-Domingo K, Force USPST (2016) Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 164(12):836–845PubMedCrossRef Bibbins-Domingo K, Force USPST (2016) Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 164(12):836–845PubMedCrossRef
13.
Zurück zum Zitat Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ et al (2019) ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 140(11):e596–e646PubMedPubMedCentral Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ et al (2019) ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 140(11):e596–e646PubMedPubMedCentral
14.
Zurück zum Zitat Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA (2022) Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 327(16):1585–1597PubMedCrossRef Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA (2022) Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 327(16):1585–1597PubMedCrossRef
15.
Zurück zum Zitat Muhlbauer V, Dallmeier D, Brefka S, Bollig C, Voigt-Radloff S, Denkinger M (2019) The pharmacological treatment of arterial hypertension in frail, older patients—a systematic review. Dtsch Arztebl Int 116(3):23–30PubMedPubMedCentral Muhlbauer V, Dallmeier D, Brefka S, Bollig C, Voigt-Radloff S, Denkinger M (2019) The pharmacological treatment of arterial hypertension in frail, older patients—a systematic review. Dtsch Arztebl Int 116(3):23–30PubMedPubMedCentral
16.
Zurück zum Zitat Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358(18):1887–1898PubMedCrossRef Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358(18):1887–1898PubMedCrossRef
17.
Zurück zum Zitat Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM et al (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 〉/=75 years: a randomized clinical trial. JAMA 315(24):2673–2682PubMedPubMedCentralCrossRef Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM et al (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 〉/=75 years: a randomized clinical trial. JAMA 315(24):2673–2682PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N et al (2015) No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med 13:78PubMedPubMedCentralCrossRef Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N et al (2015) No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med 13:78PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Welsh TJ, Gordon AL, Gladman JRF (2019) Treatment of hypertension in people with dementia: a multicenter prospective observational cohort study. J Am Med Dir Assoc 20(9):1111–1115PubMedCrossRef Welsh TJ, Gordon AL, Gladman JRF (2019) Treatment of hypertension in people with dementia: a multicenter prospective observational cohort study. J Am Med Dir Assoc 20(9):1111–1115PubMedCrossRef
20.
Zurück zum Zitat Freund TGB, Jeschke E (2016) Qualität der poststationären Arzneimittelversorgung von Patienten mit Herzinsuffizienz. In: Klauber JGM, friedirch J, Wasem J (Hrsg) Krankenhaus-Report. Schattauer, Stuttgart, S 229–246 Freund TGB, Jeschke E (2016) Qualität der poststationären Arzneimittelversorgung von Patienten mit Herzinsuffizienz. In: Klauber JGM, friedirch J, Wasem J (Hrsg) Krankenhaus-Report. Schattauer, Stuttgart, S 229–246
21.
Zurück zum Zitat Aronow WS, Ahn C, Kronzon I (1998) Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest 113(4):867–869PubMedCrossRef Aronow WS, Ahn C, Kronzon I (1998) Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest 113(4):867–869PubMedCrossRef
22.
Zurück zum Zitat Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH (2013) The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporos Int 24(10):2649–2657PubMedCrossRef Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH (2013) The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporos Int 24(10):2649–2657PubMedCrossRef
23.
Zurück zum Zitat Savarese G, Uijl A, Lund LH, Anker SD, Asselbergs F, Fitchett D et al (2021) Empagliflozin in heart failure with predicted preserved versus reduced ejection fraction: data from the EMPA-REG OUTCOME trial. J Card Fail 27(8):888–895PubMedCrossRef Savarese G, Uijl A, Lund LH, Anker SD, Asselbergs F, Fitchett D et al (2021) Empagliflozin in heart failure with predicted preserved versus reduced ejection fraction: data from the EMPA-REG OUTCOME trial. J Card Fail 27(8):888–895PubMedCrossRef
24.
Zurück zum Zitat Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ et al (2021) Effect of Empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation 144(16):1284–1294PubMedPubMedCentralCrossRef Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ et al (2021) Effect of Empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation 144(16):1284–1294PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Bruno N, Sinagra G, Paolillo S, Bonomi A, Corra U, Piepoli M et al (2018) Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. ESC Heart Fail 5(3):267–274PubMedPubMedCentralCrossRef Bruno N, Sinagra G, Paolillo S, Bonomi A, Corra U, Piepoli M et al (2018) Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. ESC Heart Fail 5(3):267–274PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G et al (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355(9215):1575–1581PubMedCrossRef Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G et al (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355(9215):1575–1581PubMedCrossRef
27.
Zurück zum Zitat Dulin BR, Krum H (2006) Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Curr Opin Cardiol 21(4):393–399PubMedCrossRef Dulin BR, Krum H (2006) Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Curr Opin Cardiol 21(4):393–399PubMedCrossRef
28.
29.
Zurück zum Zitat Veenis JF, Brunner-La RHP, Linssen GC, Geerlings PR, Van Gent MW, Aksoy I et al (2019) Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. Eur J Prev Cardiol 26(13):1399–1407PubMedPubMedCentralCrossRef Veenis JF, Brunner-La RHP, Linssen GC, Geerlings PR, Van Gent MW, Aksoy I et al (2019) Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. Eur J Prev Cardiol 26(13):1399–1407PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Komajda M, Schope J, Wagenpfeil S, Tavazzi L, Bohm M, Ponikowski P et al (2019) Physicians’ guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 21(7):921–929PubMedCrossRef Komajda M, Schope J, Wagenpfeil S, Tavazzi L, Bohm M, Ponikowski P et al (2019) Physicians’ guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 21(7):921–929PubMedCrossRef
31.
Zurück zum Zitat Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689–2696PubMedCrossRef Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689–2696PubMedCrossRef
32.
Zurück zum Zitat Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125(19):2298–2307PubMedCrossRef Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125(19):2298–2307PubMedCrossRef
33.
Zurück zum Zitat Akishita M, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T et al (2022) Frailty and outcomes in older adults with non-valvular atrial fibrillation from the ANAFIE registry. Arch Gerontol Geriatr 101:104661PubMedCrossRef Akishita M, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T et al (2022) Frailty and outcomes in older adults with non-valvular atrial fibrillation from the ANAFIE registry. Arch Gerontol Geriatr 101:104661PubMedCrossRef
35.
Zurück zum Zitat Shah SJ, Singer DE, Fang MC, Reynolds K, Go AS, Eckman MH (2019) Net clinical benefit of oral anticoagulation among older adults with atrial fibrillation. Circ Cardiovasc Qual Outcomes 12(11):e6212PubMedPubMedCentralCrossRef Shah SJ, Singer DE, Fang MC, Reynolds K, Go AS, Eckman MH (2019) Net clinical benefit of oral anticoagulation among older adults with atrial fibrillation. Circ Cardiovasc Qual Outcomes 12(11):e6212PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Gosch M, Iglseder B, Heppner HJ (2016) Falls and dementia are not contraindications for anticoagulation in older adults with atrial fibrillation. Z Gerontol Geriatr 49(5):458–459PubMedCrossRef Gosch M, Iglseder B, Heppner HJ (2016) Falls and dementia are not contraindications for anticoagulation in older adults with atrial fibrillation. Z Gerontol Geriatr 49(5):458–459PubMedCrossRef
37.
Zurück zum Zitat Bahrmann P, Harms F, Schambeck CM, Wehling M, Flohr J (2016) New oral anticoagulants for prophylaxis of stroke. Results of an expert conference on practical use in geriatric patients. Z Gerontol Geriatr 49(3):216–226PubMedCrossRef Bahrmann P, Harms F, Schambeck CM, Wehling M, Flohr J (2016) New oral anticoagulants for prophylaxis of stroke. Results of an expert conference on practical use in geriatric patients. Z Gerontol Geriatr 49(3):216–226PubMedCrossRef
38.
Zurück zum Zitat Feeney JM, Santone E, DiFiori M, Kis L, Jayaraman V, Montgomery SC (2016) Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage: a TQIP study. J Trauma Acute Care Surg 81(5:843–848CrossRef Feeney JM, Santone E, DiFiori M, Kis L, Jayaraman V, Montgomery SC (2016) Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage: a TQIP study. J Trauma Acute Care Surg 81(5:843–848CrossRef
39.
Zurück zum Zitat Feeney JM, Neulander M, DiFiori M, Kis L, Shapiro DS, Jayaraman V et al (2017) Direct oral anticoagulants compared with warfarin in patients with severe blunt trauma. Injury 48(1):47–50PubMedCrossRef Feeney JM, Neulander M, DiFiori M, Kis L, Shapiro DS, Jayaraman V et al (2017) Direct oral anticoagulants compared with warfarin in patients with severe blunt trauma. Injury 48(1):47–50PubMedCrossRef
40.
Zurück zum Zitat Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189PubMedPubMedCentralCrossRef Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189PubMedPubMedCentralCrossRef
Metadaten
Titel
Pharmakologische Therapie kardiologischer Erkrankungen im Alter
Geriatrische Perspektive
verfasst von
Univ.-Prof. Dr. med. univ. Markus Gosch
Publikationsdatum
18.07.2022
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 6/2022
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-022-02084-w

Weitere Artikel der Ausgabe 6/2022

Zeitschrift für Gerontologie und Geriatrie 6/2022 Zur Ausgabe

Journal Club

Journal Club